Showing results (61-70 of 75) with videos related to
Sort By:
Pageof 8
Journal of Clinical Medicine|May 13, 2026
Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World StudyAhmet Unlu, Asim Armagan Aydin, Esra Sazimet Kars, et al.Expert Opinion on Pharmacotherapy|August 8, 2024
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapyYusuf Ilhan, Gokhan Ucar, Mehmet Nuri Baser, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancerYusuf Ilhan, Ali Murat Tatli, Fatih Teker, et al.Journal of Cancer Research and Therapeutics|June 13, 2018
Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)Ali Inal, Hilmi Kodaz, Hatice Odabas, et al.Cancers|January 10, 2026
Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group StudySafa Can Efil, Fatih Kus, Bahadir Koylu, et al.Journal of Chemotherapy (Florence, Italy)|September 11, 2024
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaHasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, et al.Frontiers in Immunology|December 26, 2025
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter studyTaha Koray Sahin, Fatih Atalah, Bahadir Koylu, et al.Journal of Chemotherapy (Florence, Italy)|March 18, 2024
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) studyHasan Cagri Yildirim, Caner Kapar, Baris Koksal, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology GroupSalih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu, et al.Future Oncology (London, England)|October 17, 2025
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access programDeniz Tural, Oğuzcan Özkan, Eda Eylemer Mocan, et al.Pageof 8